Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Target Price at $7.60

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six research firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.60.

A number of equities analysts have recently issued reports on RXRX shares. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Morgan Stanley reduced their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its holdings in Recursion Pharmaceuticals by 7.5% in the first quarter. Rhumbline Advisers now owns 359,175 shares of the company's stock valued at $1,900,000 after purchasing an additional 25,143 shares during the last quarter. Focus Partners Wealth purchased a new stake in Recursion Pharmaceuticals in the first quarter valued at $77,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Recursion Pharmaceuticals by 183.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock worth $33,901,000 after acquiring an additional 4,149,346 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock worth $953,000 after acquiring an additional 12,372 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $890,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 5.6%

Shares of NASDAQ:RXRX traded down $0.25 during trading hours on Friday, hitting $4.20. 20,486,254 shares of the company's stock traded hands, compared to its average volume of 13,680,247. Recursion Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $12.36. The business has a fifty day moving average price of $4.91 and a 200-day moving average price of $6.41. The firm has a market capitalization of $1.71 billion, a P/E ratio of -2.75 and a beta of 0.99. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.39) EPS. Equities analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.